Guardant Health

Guardant Health is a precision oncology company that develops and commercializes blood-based genomic tests for cancer detection, treatment selection, and monitoring. Their platform analyzes circulating tumor DNA (ctDNA) from a simple blood draw to provide comprehensive genomic profiling. The company's flagship assays, such as Guardant360 and GuardantOMNI, are used by oncologists to guide targeted therapy decisions and assess resistance mechanisms. Guardant Health serves healthcare providers, pharmaceutical partners, and patients across the United States and internationally, focusing on oncology care pathways. Their tests aim to replace or complement traditional tissue biopsies, offering a less invasive alternative for genomic insight.

Guardant Health specializes in liquid biopsy and circulating free DNA (cfDNA) analysis, positioning it as a leader in non‑invasive cancer genomics. The company has obtained regulatory clearances, including FDA approvals and CE marks, for several of its assays, demonstrating adherence to diagnostic standards. It collaborates with academic medical centers and biopharmaceutical sponsors to advance biomarker discovery and clinical trial enrichment. A core competency is its high‑throughput sequencing and bioinformatics infrastructure that enables rapid turnaround of genomic reports from blood specimens.

In September 2018, Guardant Health experienced a phishing attack that compromised an employee's email account. The breach resulted in unauthorized access to protected health information for approximately 1,100 individuals. Exposed data included names, contact details, birth dates, medical diagnosis codes and a limited number of Social Security numbers. The company engaged an independent cybersecurity firm to investigate, notified regulators and affected individuals, and implemented additional security measures to prevent recurrence.